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Background: There has been increased reporting of atypical meningioma (grade II) since the World
Health Organization reclassiﬁcation in 2000, and the use of postoperative radiation therapy (RT) in
the treatment of these tumors is controversial. We evaluated patients treated at our institution to
identify patient subgroups with increased risk of recurrence that may beneﬁt from adjuvant RT.
Methods and materials: We retrospectively assessed 50 patients treated for World Health Organi-
zation grade II meningiomas between March 2000 and February 2013. Sex, race, age of diagnosis,
tumor location, performance status, size of tumor, MIB-1 index, resection status, and RT were
recorded. Patient follow-up, recurrence, and vital status were measured to assess 3-year overall
survival (OS) and recurrence free survival (RFS).
Results: The median follow-up was 37 months (range, 1-148). Female sex was associated with
decreased RFS compared with male sex (86.1% vs 100%, PZ .047). Subtotal resection demonstrated
both inferior RFS (67.5% vs 96.6%, PZ .025) and OS compared with gross total resection (70.0% vs
100%, P< .001). Tumors>4.5 cm had worse RFS than tumors4.5 cm (85.4% vs 100%, PZ .025).
Patient OS was lower in tumors with an MIB-1 index >5% than 5% (89.7% vs 100%, PZ .008).
Eastern Cooperative Oncology Group 2-4 negatively impacted OS relative to patients with an
Eastern Cooperative Oncology Group 0-1 (66.7% vs 100%, P < .001).
Conclusions: Signiﬁcantly higher rates of recurrence occurred in female sex, subtotal resection, and
tumors larger than 4.5 cm. Further studies are needed to conﬁrm these ﬁndings and determine
whether patients without any of these risk factors can undergo surgical resection without adjuvant
radiation therapy.
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plasms in adults and are the most commonly reported
central nervous system tumors.1 The incidence of menin-
giomas is approximately 6-7 in 100,000, and increases with
age. They are often an incidental ﬁnding during autopsy or
imaging.1 Pathogenesis is believed to be initiated by
genetic loss of chromosome 22q12, with tumor aggres-
siveness corresponding to degree of genomic instability.2
Meningiomas are categorized histologically based on the
World Health Organization (WHO) classiﬁcation system as
grade I (benign), grade II (atypical), and grade III
(anaplastic), representing 80%, 15% to 20%, and 1% to 3%
of all meningiomas, respectively.3
The WHO classiﬁcation system underwent a signiﬁ-
cant revision in 2000 and an update in 2007.4,5 These
changes allowed clearer deﬁnitions of variants and
resulted in a redistribution of many patients into different
classes, with better correlation between grade and tumor
behavior. Many originally “benign” or “malignant”
meningiomas were reclassiﬁed as atypical, increasing the
incidence of grade II from previously reported 5% to 7%
to the current numbers of approximately 20% to 35%.6,7
The sudden increase in reported grade II, and corre-
sponding correction of reported grades I and III, menin-
giomas has obfuscated previous clinical data regarding
outcomes and management.8
Given the increase of atypical meningiomas classiﬁed
under the new guidelines, the need for reassessment of the
current treatment approach is of growing importance.9,10
Although gross total resection (GTR) is known to be
critical, there is no consensus on the role of adjuvant
radiation therapy (RT) in the treatment of atypical menin-
giomas, resulting in inconsistencies between institutions.11
Although prospective trials are in development (European
Organization for Research and Treatment of Cancer 1308,
Radiation Therapy Oncology Group 0539), the results of
these studies will not be available for some time.12,13
In this study, we analyzed outcomes of atypical menin-
giomas diagnosed in the modern treatment era at a single
institution and assessed prognostic factors related to overall
survival (OS) and recurrence free survival (RFS), with a
focus on recurrence as these patients may warrant greater
consideration for RT.Methods
Patients
Fifty patients were treated for grade II meningiomas at
the University of Illinois Hospital in Chicago, Illinois,
between March 2000 and February 2013. This study was
approved by the University of Illinois institutional reviewboard. Electronic medical records (EMRs) were reviewed
and clinical information recorded. Sex, race, age of
diagnosis, tumor location, MIB-1 index, size of tumor,
and RT status were documented. Preoperative perfor-
mance status was retrospectively assessed using the
Eastern Cooperative Oncology Group (ECOG) score.
Meningioma grading via the 2007 WHO classiﬁcation
system was veriﬁed based on pathology reports along
with MIB-1 status. Preoperative radiology reports were
used to conﬁrm tumor location and size based on largest
single dimension.
Treatment
Extent of resection was based on surgical operative
notes and post-operative imaging. GTR was deﬁned as
Simpson 1-2 and subtotal resection (STR) as Simpson
3-4. Pursuit of RT, dose, and modality were also recor-
ded. Patient follow-up and vital status were based on
medical record review, patient contact, and Social Secu-
rity Death Index query.
Analysis
Statistical analysis was conducted using IBM SPSS
Statistics for Windows, version 22. Date of diagnosis was
deﬁned as the date of surgical resection and was used as
the starting date for OS, with survival measured until date
of death or last follow-up. RFS was measured starting at
date of resection until tumor growth was noted on routine
follow-up imaging or until symptom development, veri-
ﬁed by imaging. Kaplan-Meier curves and log-rank tests
were used to compare groups for OS and RFS. Univariate
analysis of each variable (sex, age, resection status, tumor
size, MIB-1 status, ECOG status, tumor location, and RT)
was conducted. Results from analysis were deemed sig-
niﬁcant at P <.05.
Results
Patient characteristics
A summary of patient characteristics is available in
Table 1.Medianage ofdiagnosiswas 58years (range, 26-82)
and median follow-up was 37 months (range, 1-148). The
cohort was predominately female (64%) with an ECOG of
0-1 (72%). Tumor locations were categorized as convexity
(40%), parasagittal/falx (12%), skull base (30%), intra-
ventricular (12%), and spinal (6%). Tumor size was not
available in 4 patients because of incomplete medical
records; these patients were excluded from analysis of size.
A cutoff of 4.5 cmwas used as this was the average greatest
single dimension in our patient base. Tumor size was>4.5
cm in 52%, 4.5 cm in 40%, and unknown in 8% of
Table 1 Patient and treatment characteristics
Characteristics Total
N (%)
Surgery
only N (%)
Surgery þ RT
N (%)
Gender
Male 18 (36) 12 (39) 6 (32)
Female 32 (64) 19 (61) 13 (68)
Age of diagnosis
60 y 27 (54) 15 (48) 12 (63)
>60 y 23 (46) 16 (52) 7 (37)
Race
Caucasian 19 (38) 11 (35) 8 (42)
Hispanic 12 (24) 8 (26) 4 (21)
African American 17 (34) 12 (39) 5 (26)
Asian 2 (4) 0 (0) 2 (11)
Resection
Subtotal
(Simpson III-IV)
11 (22) 3 (10) 8 (42)
Total
(Simpson I-II)
39 (78) 28 (90) 11 (58)
Size
4.5 cm 20 (40) 16 (52) 4 (21)
>4.5 cm 26 (52) 13 (42) 13 (68)
Unknown 4 (8) 2 (6) 2 (11)
MIB-1
5% 18 (36) 13 (42) 5 (26)
>5% 32 (64) 18 (58) 14 (74)
Location
Convexity 20 (40) 13 (42) 7 (37)
Parasagittal/
parafalcine
6 (12) 3 (10) 3 (16)
Skull base 15 (30) 9 (29) 6 (32)
Intraventricular 6 (12) 4 (13) 2 (10)
Spinal 3 (6) 2 (6) 1 (5)
Performance status
ECOG 0-1 36 (72) 21 (68) 15 (79)
ECOG 2-4 14 (28) 10 (32) 4 (21)
RT
Yes 19 (38)
No 31 (62)
Modality
SRS 3 (16)
IMRT 12 (63)
Unknown 4 (21)
Dose
54 Gy 9 (75)
>54 Gy 3 (25)
Recurrence 7 (14) 2 (6) 5 (26)
Death 10 (20) 6 (19) 4 (21)
Average
follow-up (mo)
Mean 41.76
Median 37
ECOG, Eastern Cooperative Oncology Group; IMRT, intensity
modulated radiation therapy; RT, radiation therapy; SRS, stereotactic
radiosurgery.
Figure 1 Kaplan-Meier analysis of recurrence free survival
comparing patients based on sex. Female patients had a statis-
tically greater risk of recurrence.
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obtained in 78% of patients. Of the cohort, 38% received
postoperative RT and 73% of those who underwent STRreceived postoperative RT. A total of 63% of patients
receiving postoperative RT received intensity modulated
radiation therapy (IMRT), whereas 16% received stereo-
tactic radiosurgery, and the remaining 21%were unknown.
The speciﬁc dose used in cases using IMRT was available
for 12 patients. The median postoperative radiation dose
used in IMRT was 54 Gy (range, 50-60) and the median
number of fractions delivered was 30 (range, 14-33). Spe-
ciﬁcs in regard to treatment approach, such as volume
delineation, could not be obtained because of limitations
of the EMR. Median time between surgery and RT was 2
months (range, 1-6).
OS and RFS
RFS was signiﬁcantly higher in men compared with
women (100% vs 88.1% at 3 years, P Z .047) (Fig 1).
Resection status had a signiﬁcant impact on RFS, with
GTR being superior to STR (96.6% vs 67.5% at 3 years,
PZ .025) (Fig 2). Tumor size had a signiﬁcant impact on
RFS (100% in 4.5 cm vs 85.4% in >4.5 cm, PZ .019)
(Fig 3). There was no beneﬁt to RFS based on MIB-1
index, location, or performance status.
GTR had a signiﬁcantly higher OS compared with STR
(100% vs 70.0% at 3 years, P < .001). Tumors with an
MIB-1 index5% had a signiﬁcantly greater OS compared
with >5% (100% vs 89.7% at 3 years, PZ .008). Patients
with a better performance status had improved OS (100% in
ECOG 0-1 vs 66.7% in ECOG 2-4, P < .001). Age and
location trended towards signiﬁcance for OS (PZ .063 and
PZ .066, respectively). There was no difference in survival
based on sex or tumor size.
Analysis of the effect of RT did not reveal a signiﬁcant
difference in OS (100% in no RT vs 100% in RT at 3 years,
P > .1) or RFS (100% in no RT vs 90% in RT at 3 years,
Figure 2 Kaplan-Meier analysis of recurrence free survival
comparing patients based on tumor size. Patients with a tumor
size >4.5 cm had a statistically greater risk of recurrence.
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RT after STR trended toward signiﬁcance in OS (33.3% in
no RT vs 85.7% in RT at 3 years, PZ .054), but no sig-
niﬁcant beneﬁt was observed for RFS (100% in no RT vs
64.3% in RT at 3 years, P> 1). IMRT dose did not appear
to have signiﬁcant beneﬁt to OS or RFS (P > .1).
Discussion
The signiﬁcant shift in rates of atypical meningiomas
as a consequence of the WHO 2000/2007 classiﬁcation
revisions has made much of the prior research examining
outcomes of atypical meningiomas inapplicable.14,15
Therefore, this study has important clinical signiﬁcance
because it reports outcomes of patients diagnosed withFigure 3 Kaplan-Meier analysis of recurrence free survival
comparing patients based on resection status. Patients with
subtotal resections had a statistically greater risk of recurrence.atypical meningioma after the reclassiﬁcation occurred in
2000. This study found that the most important prognostic
factors of recurrence were size >4.5 cm, female sex, and
subtotal resection.
The beneﬁt to both OS and RFS with regard to the
level of resection reafﬁrms the importance of GTR as the
primary prognostic indicator in the treatment of atypical
meningiomas. A recent review article demonstrated
the impact of resection on improved outcomes and
the importance of postoperative RT in those who have
undergone a STR.16 This is consistent with our near
signiﬁcant ﬁndings for OS beneﬁt from RT in STR,
though we were perhaps not able to appreciate a signiﬁ-
cant effect because of our small sample size. Although no
statistically signiﬁcant difference in RFS was discovered
from RT in STR, it was observed that STR patients that
only received surgery appeared to have better RFS than
those that received postoperative RT (100% vs 64.3%,
respectively). This seemingly paradoxical effect of RT in
the STR group is likely a manifestation of selection bias
and differences in patient characteristics. As previously
discussed, the beneﬁt of RT to RFS has been described in
a number of studies, and is generally recommended in the
setting of STR. Kaur et al performed a systematic review
of the literature speciﬁcally to evaluate the beneﬁt of
adjuvant RT in atypical and malignant meningioma.9 The
authors also recommended RT in the setting of STR,
citing beneﬁt to both OS and RFS.
Tumor size was found in our study to be a signiﬁcant
contributing factor for recurrence. Detti et al found size to
have a signiﬁcant impact on recurrence at 5 cm, which is
similar to the value used in our study.17 A study by Pizem
et al provides a possible explanation for this association,
by identifying both size and grade as predictors of brain
invasion.18 Brain invasion has been demonstrated to have
a powerful impact on recurrence and has been thoroughly
reviewed by Modha et al.10 These studies together provide
both support for our ﬁndings and rationale for the use of
adjuvant RT in larger tumors, even when GTR is obtained.
Female sex was discovered to have an adverse effect
on recurrence. To our knowledge, this study is only the
second to indicate sex as a possible prognostic factor for
recurrence.19 The incidence of meningiomas is well
known to be higher in women.11 This is thought to
correlate with the presence of androgen, estrogen, and
progesterone receptors on meningiomas.2,20 It is possible
that differing hormone levels between men and women
play a role in the risk of recurrence; further investigations
are needed to conﬁrm female sex as a negative prognostic
factor.
This study has several limitations that are inherent in a
single institution retrospective analysis. Using EMR for
patient information allows for selection bias as the deci-
sion to refer or pursue for RT varies by provider. In
addition, the availability and completeness of patient and
treatment information is limited by the dependence on
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IMRT was only available for 12 patients. Although we
found this to not be a signiﬁcant contributor to RFS or
OS, we lack power to thoroughly assess its contribution to
these endpoints. Another major limitation was the small
number of recurrences that occurred in the cohort, which
precluded us from performing an accurate multivariate
analysis examining prognostic factors. This in turn may
increase the risk of ﬁnding incidentally signiﬁcant
P values, and restricts our ability to detect subtle differ-
ences. Last, retrospective studies result in the use of
heterogeneous patient populations, using a range of
patient demographics, tumor locations, and treatment
techniques in a nonrandomized fashion. Considering
these limitations, our results are interpreted with caution.
We recommend considerations of the factors reported
here on an individual basis until the prospective trials
EORTC 1308 and RTOG 0539 are able to provide more
speciﬁc guidelines.
Conclusion
In this retrospective review, we found that female sex,
STR, and tumor size >4.5 cm negatively affect RFS. The
identiﬁcation of female sex as a risk factor for recurrence
is a novel ﬁnding. Adjuvant RT should be considered in
patients with these risk factors. Further studies are needed
to conﬁrm these ﬁndings and to elucidate if there is a
subgroup of patients with atypical meningioma in which
adjuvant RT can be safely avoided.Acknowledgments
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